COVID-19 Vaccine Booster Trial Blinded Elixir from China
Blinded liquid elixir placebo for oral intake in Phase IV COVID-19 booster trials, in 10ml sachets mimicking vaccine adjuvant taste profile. Falls under HTS 3006.93.60.00 as double-blinded clinical trial material in measured oral doses.
Duty Rate — China → United States
125%
Rate breakdown
9903.04.60100%Except as provided in heading 9903.04.61, patented pharmaceutical articles as provided for in subdivisions (c) and (d) of U.S. note 40 to this subchapter
9903.88.0325%Except as provided in headings 9903.88.13, 9903.88.18, 9903.88.33, 9903.88.34, 9903.88.35, 9903.88.36, 9903.88.37, 9903.88.38, 9903.88.40, 9903.88.41, 9903.88.43, 9903.88.45, 9903.88.46, 9903.88.48, 9903.88.56, 9903.88.64, 9903.88.66, 9903.88.67, 9903.88.68, or 9903.88.69, articles the product of China, as provided for in U.S. note 20(e) to this subchapter and as provided for in the subheadings enumerated in U.S. note 20(f)
9903.05.860%Articles provided for in subdivision (b) of U.S. note 52 to this subchapter
Import Tips
• Provide emergency use authorization or IND linked to public health emergency trials for expedited clearance
• Label with trial phase and sponsor to distinguish from waste pharmaceuticals under 3006(k)
• Test for alcohol content if any, to avoid Chapter 22 reclassification